Aignostics featured prominently this week with advances on both product and funding fronts, underscoring its role in AI-driven digital pathology. The company highlighted the April 2026 expansion of its OpenTME tumor microenvironment dataset, which now includes 3,634 whole-slide images spanning five major cancer types.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The dataset covers breast, lung and bronchus, colorectal, bladder, and liver and bile duct cancers, and comes with more than 16 million associated data points available for free download. Each slide is annotated for tissue quality control, segmentation, and cell detection and classification across nine cell types, alongside neighborhood analyses at 20 µm and 40 µm thresholds.
By making OpenTME freely accessible, Aignostics is aiming to attract academic and translational researchers and broaden adoption of its analytics in digital pathology workflows. This openness could deepen engagement with its technology stack, support external validation of its methods, and create a larger user ecosystem that may later translate into commercial opportunities.
In parallel, Aignostics announced that it has been selected for the EIC STEP Scale Up program, an equity investment initiative of the European Innovation Council. The company is one of eight start-ups put forward for potential investment by the EIC Fund and has received the STEP Seal after completing the program’s evaluation process.
Selection into this competitive EU-backed program provides institutional validation of Aignostics’ AI-driven precision medicine platform, which targets improvements in drug development and patient outcomes. It may enhance access to growth capital and strengthen the company’s standing with biopharma partners, research institutions, and healthcare providers across Europe.
If eventual EIC Fund investment materializes, Aignostics could improve its balance sheet, extend its financial runway, and support accelerated product development and market expansion. Overall, the week marked a combination of scientific data expansion and strategic funding recognition that reinforces the company’s positioning in the European health-tech and AI ecosystems.